Potential Effects of Silymarin and Its Flavonolignan Components in Patients with β-Thalassemia Major: A Comprehensive Review in 2015
Major β-thalassemia (β-TM) is one of the most common inherited hemolytic types of anemia which is caused as a result of absent or reduced synthesis of β-globin chains of hemoglobin. This defect results in red blood cells lysis and chronic anemia that can be treated by multiple blood transfusions and...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Advances in Pharmacological Sciences |
| Online Access: | http://dx.doi.org/10.1155/2016/3046373 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559370624303104 |
|---|---|
| author | Hadi Darvishi Khezri Ebrahim Salehifar Mehrnoush Kosaryan Aily Aliasgharian Hossein Jalali Arash Hadian Amree |
| author_facet | Hadi Darvishi Khezri Ebrahim Salehifar Mehrnoush Kosaryan Aily Aliasgharian Hossein Jalali Arash Hadian Amree |
| author_sort | Hadi Darvishi Khezri |
| collection | DOAJ |
| description | Major β-thalassemia (β-TM) is one of the most common inherited hemolytic types of anemia which is caused as a result of absent or reduced synthesis of β-globin chains of hemoglobin. This defect results in red blood cells lysis and chronic anemia that can be treated by multiple blood transfusions and iron chelation therapy. Without iron chelation therapy, iron overload will cause lots of complications in patients. Antioxidant components play an important role in the treatment of the disease. Silymarin is an antioxidant flavonoid isolated from Silybum marianum plant. In the present study, we reviewed clinical and experimental studies investigating the use of silymarin prior to September 1, 2015, using PubMed, ISI Web of Knowledge, Science Direct, Scopus, Ovid, and Cochrane Library databases and we evaluated the potential effects of silymarin on controlling the complications induced by iron overload in patients with β-TM. Based on the results of the present study, we can conclude that silymarin may be useful as an adjuvant for improving multiple organ dysfunctions. |
| format | Article |
| id | doaj-art-c0f5321d9dda45148bdc5a5cde0a0d9e |
| institution | Kabale University |
| issn | 1687-6334 1687-6342 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Pharmacological Sciences |
| spelling | doaj-art-c0f5321d9dda45148bdc5a5cde0a0d9e2025-02-03T01:30:15ZengWileyAdvances in Pharmacological Sciences1687-63341687-63422016-01-01201610.1155/2016/30463733046373Potential Effects of Silymarin and Its Flavonolignan Components in Patients with β-Thalassemia Major: A Comprehensive Review in 2015Hadi Darvishi Khezri0Ebrahim Salehifar1Mehrnoush Kosaryan2Aily Aliasgharian3Hossein Jalali4Arash Hadian Amree5Thalassemia Research Center, Mazandaran University of Medical Sciences, Sari, IranFaculty of Pharmacy, Thalassemia Research Center, Mazandaran University of Medical Sciences, Sari 48175-861, IranThalassemia Research Center, Mazandaran University of Medical Sciences, Sari, IranThalassemia Research Center, Mazandaran University of Medical Sciences, Sari, IranThalassemia Research Center, Mazandaran University of Medical Sciences, Sari, IranThalassemia Research Center, Mazandaran University of Medical Sciences, Sari, IranMajor β-thalassemia (β-TM) is one of the most common inherited hemolytic types of anemia which is caused as a result of absent or reduced synthesis of β-globin chains of hemoglobin. This defect results in red blood cells lysis and chronic anemia that can be treated by multiple blood transfusions and iron chelation therapy. Without iron chelation therapy, iron overload will cause lots of complications in patients. Antioxidant components play an important role in the treatment of the disease. Silymarin is an antioxidant flavonoid isolated from Silybum marianum plant. In the present study, we reviewed clinical and experimental studies investigating the use of silymarin prior to September 1, 2015, using PubMed, ISI Web of Knowledge, Science Direct, Scopus, Ovid, and Cochrane Library databases and we evaluated the potential effects of silymarin on controlling the complications induced by iron overload in patients with β-TM. Based on the results of the present study, we can conclude that silymarin may be useful as an adjuvant for improving multiple organ dysfunctions.http://dx.doi.org/10.1155/2016/3046373 |
| spellingShingle | Hadi Darvishi Khezri Ebrahim Salehifar Mehrnoush Kosaryan Aily Aliasgharian Hossein Jalali Arash Hadian Amree Potential Effects of Silymarin and Its Flavonolignan Components in Patients with β-Thalassemia Major: A Comprehensive Review in 2015 Advances in Pharmacological Sciences |
| title | Potential Effects of Silymarin and Its Flavonolignan Components in Patients with β-Thalassemia Major: A Comprehensive Review in 2015 |
| title_full | Potential Effects of Silymarin and Its Flavonolignan Components in Patients with β-Thalassemia Major: A Comprehensive Review in 2015 |
| title_fullStr | Potential Effects of Silymarin and Its Flavonolignan Components in Patients with β-Thalassemia Major: A Comprehensive Review in 2015 |
| title_full_unstemmed | Potential Effects of Silymarin and Its Flavonolignan Components in Patients with β-Thalassemia Major: A Comprehensive Review in 2015 |
| title_short | Potential Effects of Silymarin and Its Flavonolignan Components in Patients with β-Thalassemia Major: A Comprehensive Review in 2015 |
| title_sort | potential effects of silymarin and its flavonolignan components in patients with β thalassemia major a comprehensive review in 2015 |
| url | http://dx.doi.org/10.1155/2016/3046373 |
| work_keys_str_mv | AT hadidarvishikhezri potentialeffectsofsilymarinanditsflavonolignancomponentsinpatientswithbthalassemiamajoracomprehensivereviewin2015 AT ebrahimsalehifar potentialeffectsofsilymarinanditsflavonolignancomponentsinpatientswithbthalassemiamajoracomprehensivereviewin2015 AT mehrnoushkosaryan potentialeffectsofsilymarinanditsflavonolignancomponentsinpatientswithbthalassemiamajoracomprehensivereviewin2015 AT ailyaliasgharian potentialeffectsofsilymarinanditsflavonolignancomponentsinpatientswithbthalassemiamajoracomprehensivereviewin2015 AT hosseinjalali potentialeffectsofsilymarinanditsflavonolignancomponentsinpatientswithbthalassemiamajoracomprehensivereviewin2015 AT arashhadianamree potentialeffectsofsilymarinanditsflavonolignancomponentsinpatientswithbthalassemiamajoracomprehensivereviewin2015 |